Benjamin J. Huang

Benjamin J. Huang

MD

Pediatric hematologist-oncologist
Leukemia specialist and investigator

Contact me

Contact me

Dr. Benjamin J. Huang is a hematologist-oncologist who cares for children with leukemia and other cancers.

Huang's research lab aims to develop new strategies for treating leukemia using innovative drug combinations that are informed by biology and genetics. In studying blood cancers, he employs cancer modeling, targeted therapies, functional genomics (how genes affect biological processes) and biomarker identification (finding biological indicators of disease and response, such as the measurement of rare but persistent cancer within the bloodstream and bone marrow). He has a special focus on pediatric acute myeloid leukemia. He works collaboratively with other investigators at UCSF and across North America through the Children's Oncology Group.

Huang earned his medical degree at UCSF, where he also completed a residency in pediatrics and a fellowship in pediatric hematology and oncology.

  • Board Certifications

    American Board of Pediatrics, Pediatric Hematology-Oncology, 2017

    American Board of Pediatrics, Pediatrics, 2014

  • Fellowships

    UCSF, Pediatric Hematology-Oncology, 2016

  • Residencies

    UCSF, Pediatrics, 2013

  • Degree

    University of California, San Francisco, School of Medicine, 2010

  • Languages

    English

Where I see patients (1)

    Selected research

    See all research
    Decorative Caduceus

    A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With...

    MRD negative Rem-2 be defined as Rem-2 (i.e., achievement of MRD < 1% blasts by flow cytometry and resolution of extramedullary disease (for CNS disease, requires CNS 1) ) and bone marrow with MRD < 0.01% by flow cytometry. MRD ne...

    Recruiting

    More about this study
    Decorative Caduceus

    A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patien...

    The Kaplan-Meier method will be used to estimate 3-year EFS, defined as the time from study entry until induction failure, relapse, secondary malignancy, or death.

    Recruiting

    More about this study
    See all clinical trials

    Contact me

    Stress-free visits

    Accommodations. Admissions. Procedure prep. Get the info you need for smoother hospital stays.

    Prepare for your child's stay

    Share